289 related articles for article (PubMed ID: 36376842)
1. HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry.
Morsberger L; Pallavajjala A; Long P; Hardy M; Park R; Parish R; Nozari A; Zou YS
Cancer Cell Int; 2022 Nov; 22(1):350. PubMed ID: 36376842
[TBL] [Abstract][Full Text] [Related]
2. Next-generation assessment of human epidermal growth factor receptor 2 gene (ERBB2) amplification status in invasive breast carcinoma: a focus on Group 4 by use of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 testing guideline.
Hoda RS; Bowman AS; Zehir A; Razavi P; Brogi E; Ladanyi M; Arcila ME; Wen HY; Ross DS
Histopathology; 2021 Mar; 78(4):498-507. PubMed ID: 32841416
[TBL] [Abstract][Full Text] [Related]
3. Detection of ERBB2 amplification in uterine serous carcinoma by next-generation sequencing: an approach highly concordant with standard assays.
Robinson CL; Harrison BT; Ligon AH; Dong F; Maffeis V; Matulonis U; Nucci MR; Kolin DL
Mod Pathol; 2021 Mar; 34(3):603-612. PubMed ID: 33077919
[TBL] [Abstract][Full Text] [Related]
4. ERBB2 amplification status in 67 salivary duct carcinomas assessed by immunohistochemistry, fluorescence in situ hybridization, and targeted exome sequencing.
Ferguson DC; Momeni Boroujeni A; Zheng T; Mohanty AS; Ho AL; Arcila ME; Ross DS; Dogan S
Mod Pathol; 2022 Jul; 35(7):895-902. PubMed ID: 34963694
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of a Dual (Immunohistochemistry and Fluorescence In Situ Hybridization) HER2/neu Testing Strategy on Invasive Breast Cancers.
Hariri N; Zare S; Murphy J; Fadare O
Appl Immunohistochem Mol Morphol; 2021 Jan; 29(1):42-48. PubMed ID: 32205742
[TBL] [Abstract][Full Text] [Related]
6. Laboratory testing for HER2/neu in breast carcinoma: an evolving strategy to predict response to targeted therapy.
Diaz NM
Cancer Control; 2001; 8(5):415-8. PubMed ID: 11579337
[TBL] [Abstract][Full Text] [Related]
7. Chromogenic
Ali AHM; Yahya AQ; Mohammed HL
Open Access Maced J Med Sci; 2019 Jun; 7(12):1917-1925. PubMed ID: 31406529
[TBL] [Abstract][Full Text] [Related]
8. Comparison of an amplicon-based large panel next generation sequencing (NGS) assay with conventional testing methods for MET and HER2 amplification in lung and breast cancers.
Tay TKY; Tan GS; Lee SH; Sam XX; Lim TH; Ng JWK; Tan DSW; Lim TKH
Pathology; 2024 Apr; 56(3):325-333. PubMed ID: 38195375
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Next Generation Sequencing for Detecting HER2 Copy Number in Breast and Gastric Cancers.
Niu D; Li L; Yu Y; Zang W; Li Z; Zhou L; Jia L; Rao G; Gao L; Cheng G; Ji K; Lin D
Pathol Oncol Res; 2020 Oct; 26(4):2577-2585. PubMed ID: 32621174
[TBL] [Abstract][Full Text] [Related]
10.
Canterbury CR; Fernandes H; Crapanzano JP; Murty VV; Mansukhani MM; Shu CA; Szabolcs M; Saqi A
JTO Clin Res Rep; 2021 Oct; 2(10):100223. PubMed ID: 34746883
[TBL] [Abstract][Full Text] [Related]
11. Assessment of HER2 status in breast cancer: overall positivity rate and accuracy by fluorescence in situ hybridization and immunohistochemistry in a single institution over 12 years: a quality control study.
Varga Z; Noske A; Ramach C; Padberg B; Moch H
BMC Cancer; 2013 Dec; 13():615. PubMed ID: 24377754
[TBL] [Abstract][Full Text] [Related]
12. Well-differentiated invasive breast cancers with equivocal HER2 immunohistochemistry: what is the yield of routine reflex in-situ hybridization testing?
Bethune GC; Pettit AS; Veldhuijzen van Zanten D; Barnes PJ
Histopathology; 2017 May; 70(6):966-974. PubMed ID: 28032917
[TBL] [Abstract][Full Text] [Related]
13. HER2/ERBB2 copy number analysis by targeted next-generation sequencing in breast cancer.
Xia D; Kuo F; Hughes M; Lindeman N; Manning D; Files J; Strauss S; Kirkner G; Mohammed-Abreu A; Winer E; Tolaney SM; Lin NU; Dillon DA
Am J Clin Pathol; 2024 May; 161(5):436-442. PubMed ID: 38104247
[TBL] [Abstract][Full Text] [Related]
14. Comparison of HercepTest™ mAb pharmDx (Dako Omnis, GE001) with Ventana PATHWAY anti-HER-2/neu (4B5) in breast cancer: correlation with HER2 amplification and HER2 low status.
Rüschoff J; Friedrich M; Nagelmeier I; Kirchner M; Andresen LM; Salomon K; Portier B; Sredni ST; Schildhaus HU; Jasani B; Grzelinski M; Viale G
Virchows Arch; 2022 Nov; 481(5):685-694. PubMed ID: 35970977
[TBL] [Abstract][Full Text] [Related]
15. Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study.
van de Vijver M; Bilous M; Hanna W; Hofmann M; Kristel P; Penault-Llorca F; Rüschoff J
Breast Cancer Res; 2007; 9(5):R68. PubMed ID: 17922920
[TBL] [Abstract][Full Text] [Related]
16. HER2 Amplification by Next-Generation Sequencing in Lung Carcinoma: A Comparison of NGS Amplified and Non-amplified Cases by Immunohistochemistry and In Situ Hybridization.
Kıvrak H; Özakıncı H; Karasoy D; Dizbay Sak S
Balkan Med J; 2022 Jan; 39(1):21-29. PubMed ID: 34928234
[TBL] [Abstract][Full Text] [Related]
17. Correlation of HER2 gene amplification with immunohistochemistry in breast cancer as determined by a novel monoplex polymerase chain reaction assay.
Willmore C; Holden JA; Layfield LJ
Appl Immunohistochem Mol Morphol; 2005 Dec; 13(4):333-41. PubMed ID: 16280662
[TBL] [Abstract][Full Text] [Related]
18. Impact of the updated 2018 ASCO/CAP guidelines on HER2 FISH testing in invasive breast cancer: a retrospective study of HER2 fish results of 2233 cases.
Liu ZH; Wang K; Lin DY; Xu J; Chen J; Long XY; Ge Y; Luo XL; Zhang KP; Liu YH; Xu FP
Breast Cancer Res Treat; 2019 May; 175(1):51-57. PubMed ID: 30712197
[TBL] [Abstract][Full Text] [Related]
19. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization.
Tafe LJ; Janjigian YY; Zaidinski M; Hedvat CV; Hameed MR; Tang LH; Hicks JB; Shah MA; Barbashina V
Arch Pathol Lab Med; 2011 Nov; 135(11):1460-5. PubMed ID: 22032573
[TBL] [Abstract][Full Text] [Related]
20. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues.
Owens MA; Horten BC; Da Silva MM
Clin Breast Cancer; 2004 Apr; 5(1):63-9. PubMed ID: 15140287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]